Evaluation of ejection fraction in patients with Acute Myocardial Infarction in Mosul City, Iraq
Author:
Mohammed Al-Nafoly Duaa1ORCID, Mohammed Alameen Afraa2ORCID, D. Alshamaa Sarab3ORCID
Affiliation:
1. Dept. of Basic Science / College of Nursing / University of Mosul, Iraq 2. Dept. of Physiology / College of Medicine / University of Mosul, Iraq 3. Dept. of Biology / College of Science / University of Mosul, Iraq
Abstract
Between 1 January 2021 and 1 July 2021, 120 blood samples from acute myocardial infarction (AMI) patients—60 as controls and 60 patients—of both sexes who were accepted to the cardiac surgery unit at AL- Salam teaching hospital, the intensive cardiac care unit, and outpatient clinics in Mosul City/Iraq, were taken. In the presented research, the ejection fraction regarding patients with AMI was evaluated by echocardiography, and the blood-liver enzyme levels (ALP and AST \ ALT ratio) were examined in those patients. The findings indicate that patients with AMI in the age range of 35 to 45 years have a (52.41) % ejection fraction (EF) rate, which is closer to (51.344%) than it is in samples from healthy controls. In addition to that, findings indicate that patients in an age range of 46 to 56 years have heart failure with a mid-range EF (HFmrEF), with a (48.13%) percentage, whereas this heart failure type in healthy controls has been preserved ejection fraction (HFpEF) with (53.368 %). In the case of the comparison of the AST/ALT ratio and EF across all of the age groups that have been tested, the results suggest a significant level (P ≤ 0.050) relation between the ALP enzyme and EF for the patients within the (35-45 years) age group additionally, as there has been a positive and weak linear connection (r = 0.10650) and a nominal p-value (p = 0.47240) at a threshold of probability ≤ P 0.050, the link and correlation between the AST/ALT ratio and cardiac EF have been investigated.
Keywords: ALP enzyme, AMI patients, Ejection Fraction, AST \ ALT ratio.
Publisher
Clinical Biotec
Subject
Infectious Diseases,Applied Microbiology and Biotechnology,Epidemiology,Biotechnology
Reference29 articles.
1. 1.Teringova, E., Kozel, M., Knot, J., Kocka, V., Benesova, K., & Tousek, P. Relationship between TRAIL and left ventricular ejection fraction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. BioMed research international, 2018. https://doi.org/10.1155/2018/3709084 2. 2.Li, J., Zhao, Z., Jiang, H., Jiang, M., Yu, G., & Li, X. . Predictive value of elevated alanine aminotransferase for in-hospital mortality in patients with acute myocardial infarction. BMC Cardiovascular Disorders,2021; 21(1), 1-9. https://doi.org/10.1186/s12872-021-01903-z 3. 3.Baars, T., Sowa, J. P., Neumann, U., Hendricks, S., Jinawy, M., Kälsch, J., ... & Canbay, A. Liver parameters as part of a non-invasive model for prediction of all-cause mortality after myocardial infarction. Archives of Medical Science: AMS,2020; 16(1), 71-80. https://doi.org/10.5114/aoms.2018.75678 4. 4.Edem, E. Relationship between alkaline phosphatase and impaired coronary flow in patients with ST-segment elevated myocardial infarction. Journal of International Medical Research,2018; 46(9), 3918-3927. https://doi.org/10.1177/0300060518785544 5. 5.Wu, J. F., Jha, P., Doucette, S., & Abid, H. Significantly Elevated Alkaline Phosphatase Caused by Congestive Hepatopathy in the Setting of Heart Failure with Preserved Ejection Fraction. WMJ: Official Publication of the State Medical Society of Wisconsin,2022; 121(1), E14-E17.
|
|